Advanced Colorectal Carcinoma, Recurrent Colorectal Carcinoma
Conditions
Brief summary
Researchers collect specimens from advanced or recurrent colorectal cancer (CRC) patients to conduct molecular profiling and establish tumor organoids (PDOs)/ patient-derived xenografts (PDXs). The aim of this study is to identify clinical actionable targets and predict in vivo response of the tumor to targeted drugs by using PDOs/ PDXs. And the above-mentioned studies will provide the patients with potential personalized cancer treatment options.
Detailed description
Patient-derived organoid is a model that can recapitulate the histology and behavior of the cancer from which it is derived, and is increasingly used as a tool for drug development in pre-clinical settings. Clinical treatment option of colorectal cancer now is quite limited. By molecular profiling, clinical actionable alterations may be identified. And according to the genomic investigation results, we can find the matched targeted drugs, following further testing in the organoids and PDXs. This will provide an opportunity to guide the precision medicine.
Interventions
OTHERMolecular Profiling & drug testing in tumor organoids and PDXs
Molecular profiling of native tumor will be performed and analyzed by using a self-designed panel. Tumor organoids will be cultured from fresh tumor tissues and patient-derived xenografts model will be established using the tumor organoids. Drugs will be tested in the two models. And the recommendation will be communicated to the clinicians.
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Male or female patients, age 18 to 75 years old * Patients with a documented (histologically- or cytologically-proven) advanced or recurrent colorectal cancer * Patients must have Eastern Cooperative Oncology Group (ECOG) performance status =\< 1 and a life expectancy of at least 3 months * Patients, both male and female, who are either not of childbearing potential or who agree to use a medically effective method of contraception during the study and for 3 months after the last dose of study drug. * Patients with the ability to understand and give written informed consent for participation in this trial, including all evaluations and procedures as specified by this protocol.
Exclusion criteria
* Patients with any other life-threatening illness, significant organ system dysfunction, or clinically significant laboratory abnormality, which, in the opinion of the Investigator, would either compromise the patient's safety or interfere with evaluation of the safety of the study drug * Patients with abnormal coagulation function, bleeding tendency, or receiving thrombolytic or anticoagulant therapy * Patients with any other serious/active/uncontrolled infection, any infection requiring parenteral antibiotics, or unexplained fever \> 38ºC within 2 weeks prior to first study drug administration. * Patients with a history of human immunodeficiency virus (HIV) or any other immunodeficiency disease. * Patients who are currently using certain drugs that are not permitted * Patients with a psychiatric disorder or altered mental status that would preclude understanding of the informed consent process and/or completion of the necessary studies * Patients with the inability, in the opinion of the Investigator, to comply with the protocol requirements
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Identification of effective drugs or drug combinations | up to 3 years | Viability of organoid is measured using CellTiter-Glo by quantifying ATP, which indicates the presence of metabolically active cells. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of clinical actionable alterations identified in native tumor and organoids. | Up to 3 years | Genomic gene mutation numbers are identified using the Next-Generation Sequencing (NGS). |
| Correlation between organoid and PDX drug sensitivities | Up to 3 years | Size of the tumor is measured to reflect the drug response. |
Countries
China
Contacts
Primary ContactZheng Wang, MD/PhD
Backup ContactLuming Xu
Outcome results
None listed